Washington — Federal well being officers posted a warning Tuesday about deceptive statements made by biotech billionaire Dr. Patrick Quickly-Shiong, who just lately instructed podcast listeners his firm’s bladder most cancers drug could possibly deal with, treatment and even stop different forms of cancers.
The warning letter from the Meals and Drug Administration takes subject with a TV commercial and a separate podcast episode selling Anktiva, the lead product of ImmunityBio Inc. The drugmaker is one in every of a number of biotech corporations acquired by Quickly-Shiong, who additionally owns the Los Angeles Occasions.
The “FDA has decided that the TV advert and podcast are false or deceptive,” the letter says. … “Moreover, the TV advert and podcast present proof that Anktiva is meant for brand spanking new makes use of for which it lacks approval, and for which its labeling doesn’t present enough instructions to be used.”
Firm shares fell greater than 21% in Tuesday buying and selling to shut at $7.42 after the FDA letter was posted on-line.
Anktiva was authorised by the FDA in 2024 for sufferers with a hard-to-treat type of bladder most cancers. ImmunityBio has been working to win FDA approval to broaden the drug’s use to numerous different situations, together with types of lung and pancreatic most cancers.
Quickly-Shiong’s controversial statements got here throughout a January episode of “The Sean Spicer Present” podcast titled “Is the FDA blocking life-saving most cancers therapies?”
At one level in the course of the interview, Quickly-Shiong described his firm’s drug as “crucial molecule that might treatment most cancers.” A couple of minutes later, Quickly-Shiong – who’s the corporate’s govt chairman and chief medical officer – mentioned that whereas the drug is authorised for bladder most cancers, “it truly can deal with all cancers.”
Later within the episode he mentioned, “We’ve got the remedy to forestall most cancers if you happen to had been uncovered to radiation, and that is Anktiva.”
FDA regulators mentioned the statements violate federal drug advertising guidelines as a result of they “create a deceptive impression” of the drug.
Regulators additionally famous that the podcast did not include any details about dangers and uncomfortable side effects of the drug, which might embody urinary tract infections, ache, chills and pyrexia. Beneath FDA regulation, drug promotions are required to present a balanced view of a drug’s dangers and advantages.
The FDA warning, addressed to ImmunityBio CEO Richard Adcock, raises comparable considerations with a TV commercial for Anktiva. Each the advert and the podcast discuss with the corporate’s drug as a “most cancers vaccine,” which the FDA mentioned is fake.
The letter offers the corporate 15 days to right the issues and reply to the company in writing about its plans to conform. By Tuesday afternoon, a hyperlink to the podcast had been faraway from ImmunityBio’s web site.
Sarah Singleton, spokesperson for Culver Metropolis, California-based ImmunityBio, mentioned by way of e-mail that the corporate takes the FDA’s warning “very critically” and plans to “work cooperatively with the company to handle the issues raised within the letter.”
Beneath the Trump administration, the FDA has stepped up warnings in opposition to drugmakers in addition to on-line pharmacies, together with appearances by firm executives on TV exhibits and podcasts.
